Angina (Angina Pectoris) - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 14, 2018

DUBLIN--(BUSINESS WIRE)--Sep 14, 2018--The “Angina (Angina Pectoris) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Angina (Angina Pectoris) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Angina (Angina Pectoris) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 2, 2, 1, 1 and 2 respectively.

Angina (Angina Pectoris) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Featured News & Press Releases (2017-2018)

Hemostemix announces first U.S. Patients treated in phase II clinical trial Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina FDA Grants Fast Track designation to XyloCor Therapeutics Lead Candidate XC FDA Grants Fast Track designation to Angionetics’ Generx Product Candidate

Companies Featured

Angionetics Inc. Caladrius Biosciences Inc. G. Pohl-Boskamp GmbH & Co. KG Hemostemix Inc. ID Pharma Co. Ltd. Kuhnil Pharmaceutical Co. Ltd. TSH Biopharm Corporation Ltd. ViroMed Co. Ltd. XyloCor Therapeutics Inc.

Key Topics Covered

1. Introduction

2. Report Coverage

3. Overview

4. Therapeutics Development

5. Pipeline Overview

6. Pipeline by Companies

7. Products under Development by Companies

8. Therapeutics Assessment

9. Companies Involved in Therapeutics Development

10. Drug Profiles

11. Dormant Projects

12. Discontinued Products

13. Product Development Milestones

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/drgjcz/angina_angina?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180914005376/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/14/2018 11:21 AM/DISC: 09/14/2018 11:20 AM


Update hourly